The FDA granted a new indication for bevacizumab (Avastin, Genentech) in combination with chemotherapy (carboplatin and paclitaxel), followed by bevacizumab as a single agent, for the treatment of women with advanced ovarian cancer after initial surgical resection.
Specifically, bevacizumab with carboplatin and paclitaxel, followed by bevacizumab as a single agent, will be indicated for the treatment of women with stage III or IV epithelial ovarian, fallopian tube or primary peritoneal cancer